New drug development in metastatic prostate cancer.

Journal Article (Review)

In 2007, drug development in castration-resistant metastatic prostate cancer (CRPC) remains challenging, due to the number of potentially viable molecular targets and clinical trials available, the lack of established surrogates for overall survival, and competing causes of mortality. This review will highlight the highest impact phase II and phase III trials of novel agents in the current CRPC landscape, and focus on both molecular targets and clinical trial designs that are more likely to demonstrate clinical benefit. The need for tissue correlative studies for target evaluation and drug mechanism is stressed to continue to advance the field and to define biomarkers that may identify patient populations that may derive a greater benefit from these molecular agents.

Full Text

Duke Authors

Cited Authors

  • Armstrong, AJ; George, DJ

Published Date

  • July 2008

Published In

Volume / Issue

  • 26 / 4

Start / End Page

  • 430 - 437

PubMed ID

  • 18593623

International Standard Serial Number (ISSN)

  • 1078-1439

Digital Object Identifier (DOI)

  • 10.1016/j.urolonc.2007.11.006

Language

  • eng

Conference Location

  • United States